Wall Street analyst estimates for Progyny, Inc. (PGNY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 14 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (1-5) | 0.70 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $0.31 | ||
| 2026-08-06 | $0.36 | $0.33 | +7.5% |
| 2026-05-07 | $0.30 | $0.26 | +17.2% |
| 2026-02-26 | $0.15 | $0.15 | +2.0% |
| 2025-11-06 | $0.16 | $0.39 | -59.0% |
| 2025-08-07 | $0.20 | $0.17 | +17.6% |
| 2025-05-08 | $0.18 | $0.19 | -5.5% |
| 2025-02-27 | $0.12 | $0.11 | +9.1% |
Valuation Ratios
| P/E Ratio | 27.42 |
| Price / Book | 4.28 |
| EV / EBITDA | 15.02 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.6M | $105.4M | $229.7M | $344.9M | $500.6M | $786.9M | $1.09B | $1.17B | $1.29B |
| Cost of Revenue | $41.2M | $86.0M | $184.2M | $274.8M | $388.5M | $619.6M | $849.8M | $913.9M | $984.2M |
| Gross Profit | $7.4M | $19.4M | $45.5M | $70.1M | $112.1M | $167.3M | $238.8M | $253.4M | $304.5M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $18.4M | $22.9M | $35.8M | $61.7M | $79.8M | $144.0M | $176.6M | $185.9M | $219.2M |
| Operating Expenses | $18.4M | $22.9M | $35.8M | $61.7M | $79.8M | $144.0M | $176.6M | $185.9M | $219.2M |
| Operating Income | -$11.0M | -$3.5M | $9.7M | $8.3M | $32.3M | $23.3M | $62.2M | $67.5M | $85.3M |
| EBITDA | -$9.4M | -$1.6M | $11.8M | $10.3M | $33.7M | $26.0M | $73.0M | $86.4M | $100.4M |
| Interest Expense | $740,000 | $497,000 | $58,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$12.5M | -$6.9M | -$8.6M | $8.7M | $32.4M | $24.4M | $70.7M | $83.2M | $95.4M |
| Income Tax | -$3,000 | -$1.8M | $12,000 | -$37.8M | -$33.3M | -$5.9M | $8.7M | $28.9M | $36.9M |
| Net Income | -$12.5M | $661,000 | -$8.6M | $46.5M | $65.8M | $30.4M | $62.0M | $54.3M | $58.5M |
| EPS | $-2.19 | $0.01 | $-0.10 | $0.54 | $0.74 | $0.33 | $0.65 | $0.59 | $0.68 |
| EPS (Diluted) | $-2.19 | $0.01 | $-0.10 | $0.47 | $0.66 | $0.30 | $0.62 | $0.57 | $0.65 |
| Shares Outstanding (Diluted) | $5.7M | $81.6M | $83.6M | $99.1M | $100.4M | $100.0M | $100.7M | $95.4M | $89.5M |
Price
| Price | $25.86 |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALVO · GDRX · OMCL · OMDA · PHR · SDGR
Explore sector: Healthcare · Medical - Healthcare Plans
More sections of PGNY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks